CRISPR Therapeutics (CRSP)

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Aksjekursen CRISPR Therapeutics AG Common Shares (CRSP) i dag er 58,87 $, som gjenspeiler en bevegelse på −3,13 % siden markedet åpnet. Selskapets markedsverdi er $ 5,65 mrd., med et daglig handelsvolum på $ 961,22k aksjer. For investorer som følger kursutviklingen, har CRISPR Therapeutics AG Common Shares-aksjen ligget mellom 56,45 $  og 59,35 $ i dag. Den forrige lukkekursen var 60,77 $.

Er du klar til å komme i gang? Følg trinnene nedenfor, eller les vår guide om hvordan kjøpe CRISPR Therapeutics aksje på Kraken fra $10.